Member Info for Jet7

Ken’s in town with interview on Proactive.

Last November at the meeting for the dilution, Angela banged on about keeping a tight reign on finances. Then we have the share price sitting at around the 6-7p mark at the beginning of this year, this will result in nice bonus shares being allocated to directors at the beginning of next year. Finally the amount of monies raised from private investors from the dilution equated to around £250k , a years salary for JB , BEFORE BONUS!

It sucks! Shareholders wouldn’t mind if incentives were issued for performance but this sticks in the throat. What is the chairman doing? Does he represent shareholders interests?

Hello again Rhodi, likewise good to hear from you again!

Raising money? We know they are fully funded through to at least the end of phase 3 and probably to at least Feb next year. Have you now revised your outlook for the share price? As I think back you suggested 25p tops just prior to results, forgive me if I’m incorrect.

What is your view of the outlook now, where will the price stand n November?

I’ve been invested here a long time and have averaged down at a big % cost of my portfolio. I so believe in the products particularly Med as in my eyes it would be the chosen product of almost everyone.

We are getting back on track now after JB’s diabolical Proactive performance early last year. The presentation Futura put on which in my eyes was excellent has helped in raising the profile of the company.

I look at all the information that we have already been fed about Med and find it hard to think of an area which it may fail on, the safety aspect particularly this year is of great significance.

Ken and Tim come over as having left no way of wrong trial results being returned. Safety looks good, Ken expects duration to last for 35-40 minutes, quick onset, what more do you need to hear?

On top of this we have the pain relief, here’s to a great RNS at year end!

Sounds like a good place to either celebrate or commiserate on THE RNS towards the end of year!.

I’ll be joining you with my mungrel too. Where will you hang out?

Bottom line is although JB has been ridiculed for his past performance and particularly the dilution, the company is now in the position where the products themselves are doing the talking. Management seem to now be calling all the right shots in going it alone with the phase 3 trial and running it on schedule. The R&D side of the company has moved to the fore and with the excellent conferences that Futura have put on this year , institutions and Pharma are taking notice.

There have been no side effects reported and we are well over 50% of patients dosed. This says a lot along with all previous trial results on Med.

I have no doubt that as we speak interest is growing from a number of parties around the world looking at a potential blockbuster company. As Thomasbrowne points out and as I see it where will the upper usage of the product be and like Thomas I also think that this is being underestimated from what they are saying at present.

Then we look at what the company share price could be if Med and TPR are bought to market and all those posters who dismissed Ananda for his £4.20 a share valuation may be in for a shock,I am starting to see this with both products bought to market certainly valued above £2 and if a bidding war breaks out who knows!

Just been reading the chat from yesterday, like your post yesterday Dactions but I do not think the directors will be privy to any details on efficacy. The fact that JB announced that there was not any major adverse effects was in my eyes the major step forward though.

On another note it is coming up to two months since we last got a RNS on Lombards reduction in their share holding.
A large number have been sold since then with no further news, looks like others are cashing in on their 100% plus profit margin from the dilution.

The dilution and the amount of money raised for the % of equity sucks, thanks JB! I believe it will haunt all long term shareholders not allowing them out without a big loss until results. LTH have to take on all the risk. What I am saying is the 7p share will keep the share price down until we have passed the trial.

I have been very outspoken about JBs gaffs over the past year , along with crazy way of how money was raised in last years dilution and the effect this has had on LTH. However I am now starting to think that JB may be proved right but just got ahead of himself. All the safety data that has been disclosed , is a major plus for both share holders and the final outcome of the results from the phase 3 trial. Taking this information into account that has been fed to us this year along with the fact that Futura have already bought a similar product to market in CSD and I believe that we will all be looking back in 7/8 months and wishing we had invested more.

The directors are looking and sounding more and more positive in their outlook on Med, already talking about the next stage after results have been released. They are all over the trial making sure it is on track. JB states that there is much interest from pharma around the world , that must bode well.

I believe that Futura are looking for a high valuation for Med and if they get the results they are expecting I would be expecting the same.

Although the company have made errors in their placement and deal structure with CSD , this I believe will stand them in good stead when negotiating for Med.

Finally , yes they will have to raise further monies from share holders if the product is not sold , but that will be if and when the share price lies way north of where it stands today.

Where we stand today what’s not to like?

JB , very matter of fact interview, great news that there are no adverse reactions to any of the the doses! I believe we have known for the last six months that everything depends on the December results regarding the future of the company. Must say although we have heard claims in the past from JB , the directors appear to be extremely bullish on the outcome of this trial. At 15p has to be a total steal.

Last June Lombard held 17.9% stock, today their latest holding stands at 17.51%.

They have made a nice profit by selling prior to the dilution at about the 19p mark and downwards , only to buy back in at 7p then selling a large chunk at 100% plus profit margin. It will be interesting to see how much more they sell.

On another note I was impressed particularly with Tim and Ken at the presentation. They have certainly ticked a lot of the boxes and as Ken states he believes Med has a good chance with the results due at the end of year. Although there are some obvious questions to still be answered, I believe there has been much thought and preparation that has gone into the specifics and way the trial is conducted so that misleading data will not be returned.

Futura have had their fingers burnt previously and one thing for sure is they have learnt from the process and it will not happen again.

Hindsight I know , but just imagine where the price would be today without the dilution and “Punchy Numbers” gaff. Through this it only seems to have benefitted Lombard, directors as we will witness early next year and people with the odd £1 million sitting around in their bank account able to invest in the Primary bid.

Onwards we go, I am still extremely positive about the outcome.

Watch the 30 minutes or so, questions and answers, well worth it. Throws up a few issues that I was not aware of. Having said all that , I rage on about management, but credit where it’s due they have done outstandingly well to reach this point. The safety of the female partner is a massive step forward that Ken announced on Proactive, there are some issues that still have to be answered but it has to have a major chance of passing , a lot of major boxes have already been ticked.

Quite simply Rhodi, there is a chance of a rights issue or dilution, but if that’s the case you will be looking at a share price of 10 Xs where it is now after successful phase 3 , with further uplift to come from there too.

Dire management with a very good chance of potentially blockbuster products. Let’s hope they let advisors in if they pass phase 3! I truly believe we are looking at a multi-bagger this time next year.

I cannot believe how they have screwed up this share price in the last year, Nearly lost the company imho.

Good news on TPR and on to Med, thankfully I can’t see how management can mess up any further to phase 3 , this I believe will sit this time next year with a three figure share price.

And my final rant, this what I have said in my last few posts is exactly what it has lead too. A company with unbelievable products given an 80% chance of passing phase 3 now being slaughtered by the constant selling of Lombard. The light at the end of the tunnel is that there is still time to make a bundle of money here if these results are good.

Hindsight is a wonderful thing but when you also consider how late Futura left raising money through the dilution at just 7p, this time last year everything was rosey. If they were in advanced negotiations as JB stated in I believe March , why were they not at the same time looking to raise money just in case the negotiations fell through.

Once again in my eyes poor management, having said all I have I also feel that if Lombard had not supported the dilution in the way that they did the company could have failed at that point, I just question how it all played out and why it came about how it did, was it all down to mismanagement, cluelessness or something else.

All in the past now I suppose.

Markthemango, I haven’t replayed the Proactive interview in question , but if I remember correctly I think he says multiple Pharma. You need to make your own minds up!

Just found their previous holding, they have the share price in their hands, look like!

One thing that came to me when I watched the presentation yesterday , when you hear all the further information required by Pharma in the phase 3 trials, and I think back to JB saying we are in advanced negotiations, were they really? Seems like there is a lot of outstanding information still required before a deal is signed. The deal not being signed lead to the collapse in the share price and dilution at just 7p loosing both myself and other share holders big %
of their investments. On top off this , the debacle of CSD , no wonder people question the management.

From what I can see this dilution has culminated in just two parties prospering.

I have up until now been concerned by the safety of the product, I have now been reassured with the latest news from Futura. I am not surprised when Ananda posted the news that Singer have upped their % chance on the product passing phase 3,

AIMO

Can I ask if anybody has the link to phase 1 trial results, if so can they post it!

Can anyone remember What holding , percentage wise Lombard Held prior to the dilution?

Notrac, I do not dispute your figures at all. The fact is Lombard have been allowed to purchase a large percentage at 7p where as LTH could only get 1-10 unless they were able to raise money and apply for the Primary bid offer. I know the share price subsequently dropped below 6p but share holders are unlikely to have monies stashed away or have the ear of the board. A totally unlevel playing field. AIMO

If we had not had the failed punchy numbers and detailed final negotiations with several Pharma, or words similar to this we would never had the collapse and major dilution of shares at long term holders expense. Consequently this also lead to Lombard holding all the shares they have today and now selling at a large profit.

Must say the only thing I find puzzling is I’ve been expecting a further RNS to show another tranche sold off, this hasn’t appeared yet! Wonder who else is selling ?